Cardiol Therapeutics Signs Exclusive National Supplier Agreement with Medical Cannabis by Shoppers, a subsidiary of Shoppers Drug Mart

Investors

Press Releases

Cardiol Therapeutics Announces Study Results Confirm the Cardioprotective Role of its Pharmaceutical Cannabidiol Formulation in a Model of Heart Failure

April 01, 2020

Cardiol Therapeutics Announces Filing of 2019 Year-end Financial Statements and MD&A

March 26, 2020

Cardiol Therapeutics Signs Supplier Agreement with Medical Cannabis by Shoppers, a Subsidiary of Shoppers Drug Mart Inc.

March 18, 2020

Cardiol Therapeutics Receives Health Canada Approval for Phase 1 Study of its Pharmaceutically Produced Cannabidiol (CBD) Formulation

March 05, 2020

Cardiol Therapeutics’ Exclusive Manufacturing Partner Receives Three-Year Renewal and Amendment of its Cannabis Act License from Health Canada

January 15, 2020

Cardiol Therapeutics Appoints Michael J. Willner, Esq. as Business Advisor

December 18, 2019

Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to its Board of Directors

December 03, 2019

Cardiol Therapeutics comments on the Descheduling of Purisys Cannabinoid Ingredients by U.S. Drug Enforcement Agency

November 25, 2019

Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx™100

November 19, 2019

Cardiol Therapeutics Announces Completion of Manufacturing Scale-up for Commercialization of CardiolRx™100

October 01, 2019